Targeting HER2-positive breast cancer: advances and future …
The long-sought discovery of HER2 as an actionable and highly sensitive therapeutic target was a major breakthrough for the treatment of highly aggressive HER2-positive breast cancer, leading …
Therapy for small, HER2-positive breast tumors continues to be …
Follow-up results of a clinical trial that defined the standard treatment for patients with small, HER2-positive breast cancer that hasn't spread to the lymph nodes reinforce the …
Targeting HER2 in breast cancer: new drugs and paradigms on the …
About 15–20% of all breast cancers (BCs) are defined human epidermal growth factor receptor 2 (HER2)-positive, based on the overexpression of HER2 protein and/or amplification of ERBB2 …
FDA Approves New Drug Combination for ER+, HER2- Breast Cancer
The treatment combines a new drug, inavolisib (Itovebi ®), with two older breast cancer drugs, fulvestrant (Faslodex ®) and palbociclib (Ibrance ®). Inavolisib, which targets …
Emerging treatments in HER2-positive advanced breast …
In the landscape of new emerging treatments for HER2-positive breast cancer, however, new strategies aim to tackle the disease by acting on different targets, including not only HER2 (both at the extra- and intracellular …
Current and Future Management of HER2-Positive …
In the TH3RESA phase III trial, T-DM1 showed an improvement in PFS and OS compared with chemotherapy and trastuzumab according to physician's choice in 602 patients with HER2-positive breast cancer who have been exposed to …
HER2-positive breast cancer and tyrosine kinase inhibitors
Abstract. Human epidermal growth factor receptor 2 (HER2) positive breast cancer accounts for 20–25% of all breast cancers. Multiple HER2-targeted therapies have …
COMMENTS
The long-sought discovery of HER2 as an actionable and highly sensitive therapeutic target was a major breakthrough for the treatment of highly aggressive HER2-positive breast cancer, leading …
Follow-up results of a clinical trial that defined the standard treatment for patients with small, HER2-positive breast cancer that hasn't spread to the lymph nodes reinforce the …
About 15–20% of all breast cancers (BCs) are defined human epidermal growth factor receptor 2 (HER2)-positive, based on the overexpression of HER2 protein and/or amplification of ERBB2 …
The treatment combines a new drug, inavolisib (Itovebi ®), with two older breast cancer drugs, fulvestrant (Faslodex ®) and palbociclib (Ibrance ®). Inavolisib, which targets …
In the landscape of new emerging treatments for HER2-positive breast cancer, however, new strategies aim to tackle the disease by acting on different targets, including not only HER2 (both at the extra- and intracellular …
In the TH3RESA phase III trial, T-DM1 showed an improvement in PFS and OS compared with chemotherapy and trastuzumab according to physician's choice in 602 patients with HER2-positive breast cancer who have been exposed to …
Abstract. Human epidermal growth factor receptor 2 (HER2) positive breast cancer accounts for 20–25% of all breast cancers. Multiple HER2-targeted therapies have …